3367715
Last Update Posted: 2022-07-01
Recruiting has ended
All Genders accepted | 18 Years-100 Years |
10 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.
Eligibility
Relevant conditions:
MGMT-unmethylated Glioblastoma (GBM)
GBM
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov